| P50 | author | Marc Ychou | Q57036797 |
| | Martine Pugniere | Q58965992 |
| P2093 | author name string | André Pèlegrin | |
| | Véronique Garambois | |
| | Binyam Bezabeh | |
| | Elodie Foulquier | |
| | Fabienne Glaussel | |
| | Robin X Luo | |
| P2860 | cites work | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 |
| | Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor | Q28236797 |
| | Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 |
| | Radioimmunotherapy of small-volume disease of metastatic colorectal cancer | Q33341317 |
| | Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. | Q33499465 |
| | Radionuclide therapy | Q33734176 |
| | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 |
| | Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy | Q34187436 |
| | Monoclonal antibodies in the clinic. | Q34354268 |
| | Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. | Q34386601 |
| | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 |
| | An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3 | Q35227038 |
| | A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer | Q35607923 |
| | History of antibody therapy for non-Hodgkin's lymphoma | Q35622590 |
| | Altered hepatic transport of immunoglobulin A in mice lacking the J chain | Q36365566 |
| | Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model | Q36620441 |
| | Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors | Q36845371 |
| | Role of J chain and secretory component in receptor-mediated glandular and hepatic transport of immunoglobulins in man. | Q39848757 |
| | The radioresponsiveness of human tumours and the initial slope of the cell survival curve | Q40199600 |
| | Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments | Q40379395 |
| | Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis | Q40890556 |
| | Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning | Q40892824 |
| | Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen | Q40960586 |
| | Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates | Q41082594 |
| | Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system. | Q41111819 |
| | A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen | Q41385436 |
| | Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids | Q41604323 |
| | Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen | Q42499604 |
| | Human colonic adenocarcinoma cells. I. Establishment and description of a new line | Q42803939 |
| | Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? | Q44683661 |
| | The 5Rs of radiobiology | Q44952713 |
| | Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice | Q46760824 |
| | Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. | Q47822082 |
| | Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). | Q51605059 |
| | Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. | Q51606162 |
| | Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. | Q52027505 |
| | Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. | Q53390272 |
| | Marked increase in the secretion of a fully antigenic recombinant carcinoembryonic antigen obtained by deletion of its hydrophobic tail | Q54237696 |
| | Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen | Q68090479 |
| | Dimeric mouse IgA is transported into rat bile five times more rapidly than into mouse bile | Q69675986 |
| | Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation | Q70648320 |
| | Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma | Q72616623 |
| | Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies | Q73164531 |
| | Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes | Q73228020 |
| | Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies | Q73384761 |
| | Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments | Q73396357 |
| | Intraoperative immunophotodetection for radical resection of cancers: evaluation in an experimental model | Q73877506 |
| | Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer | Q74185572 |
| | Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein | Q74256284 |
| | Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice | Q74405858 |
| | Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen | Q75209095 |
| | Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA | Q93614689 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 75 | |
| P577 | publication date | 2004-10-15 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers | |
| P478 | volume | 4 | |